Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

Compared with younger patients, elderly patients with acute myeloid leukemia (AML) respond poorly to conventional chemotherapy. To determine if this poor response is due to differences in the biologic characteristics of AML in the elderly, we studied 211 patients (161 de novo, 50 secondary AML) over 55 years of age (median, 68 years) registered to a single clinical trial for previously untreated AML (SWOG 9031, Phase III randomized trial of standard dose cytosine arabinoside and daunomycin + rhG-CSF). Pretreatment leukemic blasts were karyotyped and were also analyzed for intrinsic drug resistance by quantitating expression of the multidrug resistance glycoprotein MDR1 and functional drug efflux using sensitive flow cytometric techniques. Results were correlated with clinical variables and outcome. These elderly AML patients had a high frequency of unfavorable cytogenetics (32%), MDR1 protein expression (71%), and functional drug efflux (58%); each of these factors occurred at high frequencies in both de novo and secondary AML patients and was associated with a significantly poorer complete remission (CR) rate. In multivariate analysis, secondary AML (P = .0035), unfavorable cytogenetics (P = .0031), and MDR1 (P = .0041) were each significantly and independently associated with lower CR rates. Resistant disease was associated with unfavorable cytogenetics (P = .017) and MDR1 expression (P = .0007). Strikingly, elderly MDR1(-) de novo AML patients with favorable/intermediate cytogenetics had a CR rate of 81%; with increasing MDR1 expression, CR rate decreased in this cytogenetic group. MDR1(+) secondary AML patients with unfavorable cytogenetics had a CR rate of only 12%. Thus, AML in the elderly is associated with an increased frequency of unfavorable cytogenetics and MDR1 expression, both of which independently contribute to poor outcomes. The high frequencies of these features in both de novo and secondary elderly AML patients suggest a common biologic mechanism for these leukemias distinct from that in younger patients. Investigation of biologic parameters at diagnosis in AML in the elderly may help identify patients with a high likelihood of achieving CR with conventional regimens, as well as those who may require alternate regimens designed to overcome therapy resistance.

[1]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[2]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[3]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[4]  I. T. Young.  Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[6]  J. Armitage,et al.  Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases , 1985, Cancer.

[7]  C. Coltman,et al.  Institutional performance in application of the FAB classification of acute leukemia. The southwest oncology group experience , 1985 .

[8]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[9]  D. Alberts,et al.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.

[10]  R. Gale,et al.  Acute myelogenous leukemia: recent advances in therapy , 1987 .

[11]  A. Cork,et al.  Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. , 1987, Leukemia research.

[12]  M. Oken,et al.  Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia , 1988, British journal of haematology.

[13]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[14]  C. Bloomfield,et al.  The clinical significance of karyotype in acute myelogenous leukemia. , 1989, Cancer genetics and cytogenetics.

[15]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[16]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Musto,et al.  High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P‐glycoprotein positive cells in complete remission , 1991, British journal of haematology.

[18]  O. Haas,et al.  MDR1 gene expression and treatment outcome in acute myeloid leukemia. , 1991, Journal of the National Cancer Institute.

[19]  H. Garewal,et al.  Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype , 1991, British journal of haematology.

[20]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[21]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[22]  N. Gattermann,et al.  Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes , 1992, British journal of haematology.

[23]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Sonneveld,et al.  High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. , 1993, Leukemia.

[25]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[26]  A. Delmer,et al.  Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). , 1993, Leukemia.

[27]  J. Ordonez,et al.  Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. , 1993, Blood.

[28]  P. Wood,et al.  P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival , 1994, British journal of haematology.

[29]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[30]  R. Pirker,et al.  P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. , 1994, Leukemia.

[31]  G. Marit,et al.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. , 1995, Leukemia.

[32]  N. Bown,et al.  De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. , 1995, Leukemia.

[33]  H. Clevers,et al.  The drug resistance-related protein LRP is the human major vault protein , 1995, Nature Medicine.

[34]  J. Pedersen‐Bjergaard,et al.  Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. , 1995, Blood.

[35]  J. Merlin,et al.  Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. , 1995, Blood.

[36]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[37]  F. Appelbaum,et al.  Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. , 1995, Blood.

[38]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[39]  C. Jacquelinet,et al.  Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. , 1995, Leukemia.

[40]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[41]  M. Slovak,et al.  DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. , 1996, Cytometry.

[42]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[43]  T. Grogan,et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. , 1996, Blood.